Department of Biology, State University of New York at Fredonia, Fredonia, NY, United States.
Front Immunol. 2022 Jun 10;13:902206. doi: 10.3389/fimmu.2022.902206. eCollection 2022.
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19) pandemic. Majority of COVID-19 patients have mild disease but about 20% of COVID-19 patients progress to severe disease. These patients end up in the intensive care unit (ICU) with clinical manifestations of acute respiratory distress syndrome (ARDS) and sepsis. The formation of neutrophil extracellular traps (NETs) has also been associated with severe COVID-19. Understanding of the immunopathology of COVID-19 is critical for the development of effective therapeutics. In this article, we discuss evidence indicating that severe COVID-19 has clinical presentations consistent with the definitions of viral sepsis. We highlight the role of neutrophils and NETs formation in the pathogenesis of severe COVID-19. Finally, we highlight the potential of therapies inhibiting NETs formation for the treatment of COVID-19.
新型严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是导致当前 2019 年冠状病毒病(COVID-19)大流行的罪魁祸首。大多数 COVID-19 患者病情较轻,但约 20%的 COVID-19 患者进展为重症。这些患者最终因急性呼吸窘迫综合征(ARDS)和败血症的临床表现而入住重症监护病房(ICU)。中性粒细胞胞外诱捕网(NETs)的形成也与严重的 COVID-19 有关。了解 COVID-19 的免疫病理学对于开发有效的治疗方法至关重要。在本文中,我们讨论了表明严重 COVID-19 具有符合病毒败血症定义的临床表现的证据。我们强调了中性粒细胞和 NETs 形成在严重 COVID-19 发病机制中的作用。最后,我们强调了抑制 NETs 形成的治疗方法在 COVID-19 治疗中的潜力。